Articles

Videos

Podcasts

Clinical

Repotrectinib awarded breakthrough therapy designation for patients with ROS1-positive metastatic non–small cell lung cancer previously treated with a ROS1 tyrosine kinase inhibitor and who were not previously administered platinum-based chemotherapy.

FDA Grants Breakthrough Therapy Designation to Repotrectinib for ROS1-Positive Metastatic NSCLC  

The SKYSCRAPER-01 trial evaluating the drug plus Tecentriq demonstrates that it did not meet its co-primary endpoint of progression-free survival.

Study Results Show Genentech’s Tiragolumab Did Not Meet Primary Endpoints

The agent is the first oral therapy for this indication.

Using Mobocertinib to Treat Advanced NSCLC With EGFR Exon 20 Insertion Mutations

Additionally, the safety profile in DESTINY-Lung01 was consistent with previous clinical trials with no new safety concerns identified.

Enhertu Granted Priority Review for Previously Treated HER2-Mutant Metastatic Non-Small Cell Lung Cancer

The investigational selective, covalent, and orally bioavailable KRASG12C¬ inhibitor shows a 57% confirmed overall response rate at the recommended dose of 200 mg twice daily.

Novartis Releases Positive Phase 1b/2 Clinical Data for JDQ443 for Treatment of NSCLC

Based on event-free survival and pathologic complete response results, the FDA approved nivolumab in combination with platinum-doublet chemotherapy in March 2022.

Nivolumab, Chemotherapy Improves Event-Free Survival in Resectable Non-Small Cell Lung Cancer

Results show that 64% of individuals treated with lorlatinib were without disease progression after 3 years compared with about 19% of those treated with crizotinib (Xalkori).

Pfizer’s Lorbrena for Treatment of NSCLC Shows Positive Data in Phase 3 Trial 

Clinical data from phase 1/2 LIBRETTO trial show evidence of meaningful clinical outcomes for patients, including those with difficult-to-treat brain metastases.

Lilly Presents Updated Data on Retevmo in Advanced RET Fusion-Positive NSCLC

Sotorasib demonstrates clinical benefit and prolonged tumor response seen, with a 40.7% objective response rate.

Amgen’s Lumakras Study Results Show Long-Term Efficacy for Treatment of NSCLC

Melissa Johnson, MD, program director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses her presentation at the Community Oncology Alliance 2022 conference on new drugs in the non-small cell lung cancer space.

Overview of New Drugs in Non-small Cell Lung Cancer, Implications for the Treatment Landscape

® Lung Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancer that begins on the lungs, including non-small cell lung cancer and small cell lung cancer.